Show simple item record

dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorFizazi, K.en
dc.creatorPavlidis, Nicholasen
dc.creatorFizazi, K.en
dc.date.accessioned2018-06-22T09:54:14Z
dc.date.available2018-06-22T09:54:14Z
dc.date.issued2009
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/42258
dc.description.abstractCarcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests as an heterogenous group of mainly epithelial cancers recognised by distinct clinicopathological entities. The diagnostic work-up includes extensive histopathology investigations and modern imaging technology. Nevertheless, the primary tumour remains undetected most of the time. Molecular diagnosis with DNA microarrays demonstrates high sensitivity, but its prognostic contribution is still uncertain. Certain clinicopathological CUP entities are considered as favourable sub-sets responding to systemic platinum-based chemotherapy or managed by locoregional treatment. These sub-sets are: the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, peritoneal papillary serous adenocarcinomatosis in females, poorly differentiated neuroendocrine carcinomas, isolated axillary node adenocarcinomas in females or cervical nodal involvement by a squamous cell carcinoma. Patients who belong to the non-favourable sub-sets have a worse prognosis. © 2008 Elsevier Ireland Ltd. All rights reserved.en
dc.language.isoengen
dc.sourceCritical reviews in oncology/hematologyen
dc.subjectAntineoplastic agenten
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subjectTamoxifenen
dc.subjectHumansen
dc.subjectCancer patienten
dc.subjectCancer combination chemotherapyen
dc.subjectCarboplatinen
dc.subjectNeoplasm stagingen
dc.subjectPaclitaxelen
dc.subjectPrognosisen
dc.subjectClinical trialen
dc.subjectGemcitabineen
dc.subjectTaxane derivativeen
dc.subjectPlatinumen
dc.subjectCancer stagingen
dc.subjectReviewen
dc.subjectCancer surgeryen
dc.subjectErlotiniben
dc.subjectMetastasisen
dc.subjectCancer diagnosisen
dc.subjectCancer mortalityen
dc.subjectCancer radiotherapyen
dc.subjectBone metastasisen
dc.subjectIrinotecanen
dc.subjectRisk factorsen
dc.subjectClinical featureen
dc.subjectLymphatic metastasisen
dc.subjectHistopathologyen
dc.subjectCancer incidenceen
dc.subjectMediastinum lymph nodeen
dc.subjectDiagnosisen
dc.subjectTreatmenten
dc.subjectBevacizumaben
dc.subjectAdenocarcinomaen
dc.subjectParaaortic lymph nodeen
dc.subjectSquamous cell carcinomaen
dc.subjectDiagnostic valueen
dc.subjectUnknown primaryen
dc.subjectCancer localizationen
dc.subjectCarcinomaen
dc.subjectTumor markeren
dc.subjectEndoscopyen
dc.subjectProstate specific antigenen
dc.subjectProtein blood levelen
dc.subjectDifferentialen
dc.subjectEarly diagnosisen
dc.subjectPatient referralen
dc.subjectCancer of unknown primaryen
dc.subjectDna microarrayen
dc.subjectAdjuvant therapyen
dc.subjectDiagnostic imagingen
dc.subjectCancer tissueen
dc.subjectChromosome aberrationen
dc.subjectPrimary tumoren
dc.subjectBrain canceren
dc.subjectEndocrine tumoren
dc.subjectTissue differentiationen
dc.subjectUterine cervixen
dc.titleCarcinoma of unknown primary (CUP)en
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.critrevonc.2008.09.005
dc.description.volume69
dc.description.issue3
dc.description.startingpage271
dc.description.endingpage278
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.gnosis.orcid0000-0002-2195-9961


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record